
               
               
               CLINICAL PHARMACOLOGY
               
                  The mechanism of action of buspirone is unknown. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. 
       
 
  In vitro preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT
       
 
  1A) receptors. Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding 
       
 
  in vitro or 
       
 
  in vivo when tested in preclinical models.
      

 
                  Buspirone has moderate affinity for brain D2-dopamine receptors. Some studies do suggest that buspirone may have indirect effects on other neurotransmitter systems.
                  Buspirone is rapidly absorbed in man and undergoes extensive first-pass metabolism. In a radiolabeled study, unchanged buspirone in the plasma accounted for only about 1% of the radioactivity in the plasma. Following oral administration, plasma concentrations of unchanged buspirone are very low and variable between subjects. Peak plasma levels of 1 to 6 ng/mL have been observed 40 to 90 minutes after single oral doses of 20 mg. The single-dose bioavailability of unchanged buspirone when taken as a tablet is on the average about 90% of an equivalent dose of solution, but there is large variability.
                  The effects of food upon the bioavailability of buspirone have been studied in eight subjects. They were given a 20 mg dose with and without food; the area under the plasma concentration-time curve (AUC) and peak plasma concentration (C
       
 
  max) of unchanged buspirone increased by 84% and 116%, respectively, but the total amount of buspirone immunoreactive material did not change. This suggests that food may decrease the extent of presystemic clearance of buspirone (See 
       
 
  DOSAGE AND ADMINISTRATION). 
      

 
                  A multiple-dose study conducted in 15 subjects suggests that buspirone has nonlinear pharmacokinetics. Thus, dose increases and repeated dosing may lead to somewhat higher blood levels of unchanged buspirone than would be predicted from results of single-dose studies.
                  An 
       
 
  in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins. It was also observed that aspirin increased the plasma levels of free buspirone by 23%, while flurazepam decreased the plasma levels of free buspirone by 20%. However, it is not known whether these drugs cause similar effects on plasma levels of free buspirone 
       
 
  in vivo, or whether such changes, if they do occur, cause clinically significant differences in treatment outcome. An 
       
 
  in vitro study indicated that buspirone did not displace highly protein-bound drugs such as phenytoin, warfarin, and propranolol from plasma protein, and that buspirone may displace digoxin.
      

 
                  Buspirone is metabolized primarily by oxidation, which 
       
 
  in vitro has been shown to be mediated by cytochrome P450 3A4 (CYP3A4). (See 
       
 
  PRECAUTIONS: 
       
 
  Drug Interactions). Several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP), are produced. In animal models predictive of anxiolytic potential, 1-PP has about one quarter of the activity of buspirone, but is present in up to 20-fold greater amounts. However, this is probably not important in humans: blood samples from humans chronically exposed to buspirone do not exhibit high levels of 1-PP; mean values are approximately 3 ng/mL and the highest human blood level recorded among 108 chronically dosed patients was 17 ng/mL, less than 1/200th of 1-PP levels found in animals given large doses of buspirone without signs of toxicity.
      

 
                  In a single-dose study using 
       
 
  14C-labeled buspirone, 29% to 63% of the dose was excreted in the urine within 24 hours, primarily as metabolites; fecal excretion accounted for 18% to 38% of the dose. The average elimination half-life of unchanged buspirone after single doses of 10 to 40 mg is about 2 to 3 hours.
      

 
               
               
               
                  
                     
                     
                     Special Populations
                     
                        
                           Age and Gender Effects 
                        
                        After single or multiple doses in adults, no significant differences in buspirone pharmacokinetics (AUC and C
         
 
  max) were observed between elderly and younger subjects or between men and women.
        

 
                        
                           Hepatic Impairment
                        
                        After multiple-dose administration of buspirone to patients with hepatic impairment, steady-state AUC of buspirone increased 13-fold compared with healthy subjects (see 
         
 
  PRECAUTIONS).
        

 
                        
                           Renal Impairment
                        
                        After multiple-dose administration of buspirone to renally impaired (CI
         
 
  cr = 10-70 mL/min/1.73 m
         
 
  2) patients, steady-state AUC of buspirone increased 4-fold compared with healthy (Cl
         
 
  cr >80 mL/min/1.73 m
         
 
  2) subjects (see 
         
 
  PRECAUTIONSÂ ).
        

 
                        
                           Race Effects
                        
                        The effects of race on the pharmacokinetics of buspirone have not been studied.
                     
                     
                  
               
            
         